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scientists reported that dihydroartemisinin also has another advantage of killing multiple cancer c
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Objective: To evaluate the inhibitory effect of dihydroartemisinin on neuroblastoma cell
line SH-SY5Y, explore the possible mechanism of dihydroartemisinin against neuro-
blastoma cells.
Methods: The cell viability of dihydroartemisinin treated SH-SY5Y cells was examined
by MTT assay and morphology of cells was observed by using inverted microscope. Cell
cycle was examined with ﬂowcytometry assay, then cyclin D1 and caspase-3 proteins
expression was detected by ELISA and western blotting assay.
Results: MTT analysis results showed that cell viability signiﬁcantly decreased after
exposure to 0.05, 0.50, 5.00 and 50.00 mmol/L dihydroartemisinin in a dose-dependent
manner, and the lower density of cells was observed in treated groups. The number of
cells in sub-G1 phase was increased after treatment with different doses of dihy-
droartemisinin compared with the control group. The expression of cyclin D1 protein was
decreased, while the expression of caspase-3 protein was increased in treated group.
Conclusions: Dihydroartemisinin could inhibit the proliferation through stopping the
cell cycle and inducing the apoptosis in neuroblastoma SH-SY5Y cells.1. Introduction
Neuroblastoma is one of the most common malignant solid
tumors in infants and young children [2]. So far, there has been
no effective treatment. Surgery, chemotherapy and radiotherapy
are the three main methods clinically. Among them,
chemotherapy drugs could kill the tumor cells, but at the sametime, they can also bring huge toxic side effects, and lead to
serious impact on physical and mental health of children.
Therefore, it is necessary to ﬁnd a kind of chemotherapeutic
drugs with low toxicity and high efﬁciency for neuroblastoma
treatments.
Dihydroartemisinin (DHA), a main active metabolite
extracted from artemisinin, has been widely used as an anti-
malaria drug clinically. It possesses many advantages such as
good absorption, wide distribution, rapid excretion and meta-
bolism, high efﬁciency and low toxicity, etc. In the study by Hou
et al., the result showed that DHA has less effects on the growth
of normal cells [3], but it could signiﬁcantly kill multiple cancer
cells in vivo [4].
The present study aimed to explore the inhibition on neuro-
blastoma SH-SY5Y cells proliferation by DHA using MTT
assay and morphology detection, thereby investigating the
possible mechanisms responsible for DHA-induced inhibitionrticle under the CC BY-NC-ND license (http://
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blotting assay.
2. Materials and methods
2.1. Drug and reagents
In this study, DHA was purchased from Chengdu Okay Co.,
Ltd. Dulbecco’s modiﬁed Eagle medium was from Hyclone Co.
(Logan, Utah, USA). Trypsin (1:250) and fetal bovine serum
were from Invitrogen Co. (Carlsbad, CA, USA). Dimethylsulf-
oxide (DMSO) and MTT used in the experiment were from
Sigma Chemical Co. (St. Louis, MO, USA). Cyclin D1, caspase-
3 and b-actin antibodies were purchased from Santa Cruz Co.
DHA was dissolved in DMSO solution at 50 mmol/L and
reserved in refrigerator.
2.2. Cell line and cell culture
The human neuroblastoma cell line SH-SY5Y was provided
by Scientiﬁc Research Center of Jinlin Medical University. The
experiments using human cell lines were approved by Jinlin
Medical University Ethics Committee. The cryopreserved SH-
SY5Y cells were placed in a 37 C water bath and vibrated
until dissolved. After centrifugalization at 1000 r/min for 5 min,
the cell suspension was then cultured in the Dulbecco’s modiﬁed
Eagle medium supplemented with 10% fetal bovine serum at
37 C, in a humidiﬁed atmosphere of 95% O2 and 5% CO2. The
cells were subcultured every 2 or 3 days.
2.3. Cell viability assay
Cells were cultured in 96-well plate at a density of 8 × 103
cells/well and incubated for 24 h. Various doses of DHA (0.00,
0.05, 0.50, 5.00 and 50.00 mmol/L) were used to treat the cells
for 24, 48 and 72 h. After incubation, 20 mL MTT (5 mg/mL)
reagent was added to each well for 4 h at 37 C. Then the MTT
liquid was replaced, and 150 mL DMSO was added and the
mixture was agitated for 10 min. Absorbance was read at a
wavelength of 490 nm by using an EL×800 Universal Micro-
plate Reader (BIO-TEK, Norcross, GA, USA). Experiments
were performed in triplicate, and cell viability was calculated as
a percentage of the control (the group treated with 0.00 mmol/L
DHA).
2.4. The morphology of SH-SY5Y cells
Cells were cultured overnight in 25 cm2 ﬂask, and then
treated with 0.05, 0.50, 5.00 and 50.00 mmol/L DHA for 24 h,
respectively. Cells treated with vehicle served as control. Photos
were taken under inverted microscope (Olympus Corporation,
Japan).
2.5. Cell cycle assay
Cells were collected after 24 h treatment with DHA at 0.05,
0.50, 5.00 and 50.00 mmol/L, respectively, and washed with
phosphate-buffered saline solution, then resuspended in 80%
ice-cold methanol and incubated at −20 C overnight. Cells were
stained with buffered saline solution containing 20 mg/mL pro-
pidium iodide for 30 min, ﬁltered with 300-mesh nylon screen,and then analyzed with ﬂow cytometry (Epics-XL, Beckman
Coulter Inc., Bria, CA, USA).
2.6. ELISA assay
The SH-SY5Y cells were divided into 5 groups, and treated
with 0.00, 0.05, 0.50, 5.00 and 50.00 mmol/L DHA for 24 h,
respectively. The supernatant was collected for experiments, and
then incubated with coating buffer at ratio of 1:1 overnight at
4 C. After closure, the cyclin D1 and caspase-3 antibodies
(1:1000 dilution) were separately added, followed by continued
incubation overnight at 4 C. Then the cells were incubated at
37 C for 1.5 h after adding secondary antibody (1:1000 dilu-
tion). Diaminobenzidine was added for 5 min; when the color
was brown, the absorbance value was determined by automatic
microplate reader (MDC, USA) at 492 nm.
2.7. Western blotting
SH-SY5Y cells were collected after 0.05, 0.50, 5.00 and
50.00 mmol/L DHA treatments, and lysed with a lysis buffer
(50 mmol/L Tris, 150 mmol/L NaCl, 2 mmol/L ethylene
diamine tetraacetic acid, 10% glycerol, 1% Triton X-100, 1%
protease inhibitor mixture and 1 mmol/L phenylmethanesulfonyl
ﬂuoride). Fifty micrograms of total protein from each lysate
were separated through SDS-PAGE and transferred to mem-
branes. The membranes were incubated with the primary anti-
bodies against b-actin, cyclin D1 and caspase-3. b-actin, as a
loading control (1:1000; SANTA CRUZ, USA), was used
overnight at 4 C. Primary antibody binding was detected with
anti-rabbit immunoglobulin G conjugated to horseradish
peroxidase and visualized by an enhanced chemiluminescence
detection system (Pierce, Rockford, IL, USA). Results were
analyzed using Image-Pro Plus image analysis and management
systems (USA).
2.8. Statistical analysis
Data were analyzed by the SPSS 17.0 software and expressed
as mean ± SD. Statistical comparisons between different groups
were done by using One-way ANOVA. The statistical signiﬁ-
cance was determined at P < 0.05.
3. Results
3.1. The effects of DHA on the proliferation of SH-SY5Y
cells
The results of MTT assay showed that different concentra-
tions of DHA could inhibit the growth of SH-SY5Y cells at 24,
48 and 72 h, respectively; the proliferation was signiﬁcantly
decreased in 0.50, 5.00 and 50.00 mmol/L DHA treated groups
(P < 0.05, P < 0.01). DHA could inhibit the growth of SH-
SY5Y cells in a dose-dependent manner. The inhibition was
the most obvious at 24 h, therefore 24 h was taken as the proper
time for the follow-up experiments (Table 1).
The morphology of cells was observed under the inverted
microscope. The number of adherent cells in DHA treated
groups was signiﬁcantly decreased compared with the control
group, and at the same time, the density of cells was decreased
with increasing concentrations of DHA (Figure 1).
Table 1
Effects of DHA on the growth of SH-SY5Y cells. %.
Groups The rates of proliferation
24 h 48 h 72 h
Control group 100.00 ± 1.36 100.00 ± 4.54 100.00 ± 4.61
0.05 mmol/L
DHA group
94.52 ± 1.45 98.49 ± 1.53 90.76 ± 3.38
0.50 mmol/L
DHA group
93.15 ± 4.41* 95.46 ± 1.58* 89.23 ± 3.44*
5.00 mmol/L
DHA group
86.30 ± 1.58** 92.43 ± 4.92** 83.07 ± 3.70**
50.00 mmol/L
DHA group
79.45 ± 3.45** 84.85 ± 3.57** 84.61 ± 1.81**
*: P < 0.05 compared with control group. **: P < 0.01 compared with
control group. Data were expressed as mean ± SD.
Figure 1. DHA inhibited the growth of SH-SY5Y cells (×200).
A: Control group; B: Cells treated with 50 mmol/L DHA.
Table 3
The secretion of cyclin D1 and caspase-3 proteins in supernatant.
Groups Absorbance value
Cyclin D1 Caspase-3
Control group 0.90 ± 0.03 1.05 ± 0.04
0.05 mmol/L DHA group 0.85 ± 0.12 1.06 ± 0.03
0.50 mmol/L DHA group 0.83 ± 0.04 1.07 ± 0.02
5.00 mmol/L DHA group 0.82 ± 0.01 1.08 ± 0.01
50.00 mmol/L DHA group 0.77 ± 0.07* 1.09 ± 0.02
*: P < 0.05 compared with control group. Data were expressed as
mean ± SD.
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Figure 2. DHA affected the expression of cyclin D1 and caspase-3 pro-
teins in SH-SY5Y cells.
A: The expression of cyclinD1 and caspase-3 proteins; B: The level of
cyclin D1 protein expressed; C: The level of caspase-3 protein expressed. *:
P < 0.05 compared with control group; **: P < 0.01 compared with control
group. Data were expressed as mean ± SD.
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The number of SH-SY5Y cells in sub-G1 phase was
increased with the increase in concentrations of DHA. In this
phase, compared with the control group, the cells of 50 mmol/L
DHA group were signiﬁcantly increased (P < 0.05). The number
of SH-SY5Y cells in G0/G1 phase was increased at ﬁrst and then
decreased. The number of SH-SY5Y cells in S and G2/M phases
was decreased (Table 2).Table 2
Effect of DHA treatment on cell cycle of SH-SY5Y cells. %.
Groups Cell cycle
Sub-G1 G0/G1 S G2/M
Control group 2.08 ± 0.28 53.78 ± 1.23 23.17 ± 1.17 20.97 ± 1.03
0.05 mmol/L DHA group 4.98 ± 0.29 56.05 ± 1.32 23.02 ± 1.25 15.95 ± 1.21
0.50 mmol/L DHA group 8.46 ± 0.53 55.94 ± 2.11 22.74 ± 1.38 12.86 ± 0.98
5.00 mmol/L DHA group 10.11 ± 0.81 55.24 ± 3.35 22.36 ± 2.02 12.29 ± 0.85
50.00 mmol/L DHA group 15.28 ± 1.19* 53.26 ± 2.28 19.42 ± 1.01 11.94 ± 1.04
*: P < 0.05 compared with control group. Data were expressed as mean ± SD.3.3. The expression of cyclin D1 and caspase-3 proteins
The results of ELISA showed that the secretion of cyclin D1
protein was decreased in cultured supernatant; when compared
with control group, the secretion of cyclin D1 in 50 mmol/L
DHA group was signiﬁcantly reduced (P < 0.05). However, the
secretion of caspase-3 protein was increased in all DHA treated
groups compared with the control group without signiﬁcant
difference (P > 0.05) (Table 3).The results of western blotting showed that the expression of
cyclin D1 was decreased in DHA treated groups, and the dif-
ference was statistically signiﬁcant (P < 0.05, P < 0.01), while
caspase-3 protein was increased in different DHA doses treated
groups when compared with control group, and the difference
between 50 mmol/L DHA group and control group was statis-
tically signiﬁcant (P < 0.01) (Figure 2).4. Discussion
Artemisinin is a kind of compound which contains the
peroxide groups and is extracted from Artemisia annua L. It is
an effective and famous natural product for clinical treatment of
malaria, otherwise as a new anti-tumor agent [5]. DHA is the
main active metabolite of artemisinin in vivo, whose oral
bioavailability is 10 times higher than that of artemisinin, and
the anti-malaria effects are stronger than artemisinin by 4–8
Ling Qi et al./Asian Pac J Trop Biomed 2016; 6(4): 279–282282times; at the same time, DHA also has an obvious anti-tumor
activity [5–8]. However, the inhibitory effect of DHA on the
growth of SH-SY5Y cells is still unknown.
We studied how various doses of DHA affected the prolif-
eration of SH-SY5Y cells, and thereby explored its anti-tumor
function. The results revealed that different concentrations of
DHA can signiﬁcantly inhibit the growth of neuroblastoma cells
at indicated time points, and the inhibitory effect was obviously
dose-dependent. The density of cells was obviously decreased
with increased doses of DHA. These results showed that DHA
inhibited the growth of SH-SY5Y cells in a concentration
dependent manner.
The results regarding cell cycle showed that the number of
SH-SY5Y cells was increased in sub-G1 phase, increased and
then decreased in G0/G1 phase, decreased in S and G2/M phases
with the increased concentrations of DHA. As it is known to all,
the growth of the cells is regulated by cyclins and cyclin-
dependent kinase inhibitor, among which cyclin D1 plays a
positive regulatory role in the growth of cells [8]. Hosoya et al.
and Mao et al. reported that DHA stopped the cell cycle at G0/
G1 phase, and made a problem in the conversion of G1/S
junction [9,10]. Cyclin D1 is an important protein which
regulates the conversion of G1/S junction; blocking and
knocking out cyclin D1 could stop the cell cycle at G0/G1
phase, and induce apoptosis [11]. Therefore, our results
suggested that DHA could down-regulate the expression and
secretion of cyclin D1 protein to stop cell cycle and inhibit the
proliferation of SH-SY5Y cells.
Apoptosis is a process of programmed cell death
controlled by multiple factors, which is caused by a series of
intracellular proteins. The caspases play an important role in
the process of cell apoptosis [12]. Although caspase is rarely
expressed in most tumor tissues [13], it is the only way for
the caspases cascade reaction, and it is also the key
molecule in apoptosis. Casepase-3 is an important protein
which exists in the form of proenzyme in cytoplasm; it is
activated when apoptosis is induced in tumor cells [14]. DHA
induced the apoptosis through caspases pathway [15]. Our
results showed that there was an increase in the secretion
and expression of caspase-3 protein by SH-SY5Y cells,
which certiﬁed that DHA could induce apoptosis through
caspase-3 activation.
In conclusion, DHA could induce apoptosis of neuroblas-
toma SH-SY5Y cells through down-regulating cylin D1 and
activating caspase-3, thereby inhibiting the growth of neuro-
blastoma cell. However, because there are many factors
affecting the growth of tumor cell, and among them, the cell
cycle and apoptosis were preliminarily studied in the present
study, further investigation of the mechanism of DHA against
tumor cells is still needed in the future study.
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